Technology
Viking Therapeutics Announces Positive Top-Line Results From Phase 2 Venture-Oral Dosing Trial Of Vk2735 Tablet Formulation In Patients With Obesity
By PR Newswire
Study Achieves Primary and Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight with Once-Daily VK2735 Dosing as Compared to Placebo
Up to 12.2% (26.6 lbs) Mean Weight Loss Observed After 13 Weeks of VK2735 Treatment ...Read more
